By Fineline Cube CANbridge Pharmaceuticals Inc. (HKG: 1228) announced that its rare disease drug Livmarli (Maralixibat Chloride Oral Solution) has been granted reimbursement approval by Taiwan’s National Health Insurance Administration (NHIA), with coverage set to take effect on September 1, 2026.
Reimbursement Milestone
| Item | Detail |
|---|---|
| Agency | National Health Insurance Administration (NHIA), Taiwan |
| Approval Type | Reimbursement approval |
| Product | Livmarli (Maralixibat Chloride Oral Solution) |
| Indications | Alagille syndrome (ALGS); progressive familial intrahepatic cholestasis (PFIC) |
| Announcement Date | 18 Aug 2026 |
| Coverage Effective Date | 1 Sep 2026 |
Drug Profile & Mechanism of Action
- Molecule: Maralixibat chloride, oral solution.
- Mechanism: Minimally absorbed ileal bile acid transporter (IBAT) inhibitor that blocks the enterohepatic circulation of bile acids.
- Therapeutic Effect: Reduces bile acid levels in the liver and serum, decreases resultant liver injury, and alleviates cholestatic pruritus (extreme itching).
- Indications: Treatment of Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC).
- Regulatory Footprint: Approved in China (Mainland, Hong Kong and Taiwan), the United States and the European Union.
Market Impact & Outlook
- Rare Disease Access: NHIA reimbursement removes a key affordability barrier for ALGS and PFIC patients in Taiwan, where both conditions are ultra‑rare and treatment options remain limited.
- Commercial Trajectory: Coverage effective September 1 positions Livmarli for near‑term uptake within Taiwan’s single‑payer system, adding a reimbursed indication to CANbridge’s rare disease portfolio.
- Global Validation: Prior approvals across China, the U.S. and the EU reinforce the clinical and regulatory foundation supporting Livmarli’s expansion in additional markets.
- Strategic Positioning: For CANbridge Pharmaceuticals (HKG: 1228), the milestone strengthens its rare disease commercialization platform and broadens the product’s lifecycle value in Greater China.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding reimbursement implementation and commercial expectations for Livmarli. Actual results may differ due to risks including policy changes, market adoption and competitive dynamics.-Fineline Info & Tech